<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lee MY</submitter><funding>NIDCR NIH HHS</funding><pagination>e014067</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12863322</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Neoadjuvant PD-1/PD-L1 blockade yields robust efficacy in advanced cutaneous squamous cell carcinoma (cSCC), yet many patients fail to achieve a complete or major pathologic response. The reasons why some patients experience response but others do not are unclear.&lt;h4>Methods&lt;/h4>We profiled cSCC specimens before, after 1 dose, and after 3-4 doses of PD-1/PD-L1 blockade to uncover resistance mechanisms and predict therapeutic response. In total, 27 patients across three cohorts, including two phase II trials, were studied. We created 1.7 mm tissue-core microarrays and performed single-cell spatial transcriptomics, including spatial clustering, gene-set enrichment, and spatial correlation analyses.&lt;h4>Results&lt;/h4>After profiling all samples, six distinct spatial niches eme</pubmed_abstract><journal>Journal for immunotherapy of cancer</journal><pubmed_title>Single-cell spatial transcriptomics uncovers niches that govern response to PD-1/PD-L1 blockade in cutaneous squamous cell carcinoma.</pubmed_title><pmcid>PMC12863322</pmcid><funding_grant_id>R35 DE030054</funding_grant_id><pubmed_authors>Colevas AD</pubmed_authors><pubmed_authors>Shin JH</pubmed_authors><pubmed_authors>Martinez Ramirez L</pubmed_authors><pubmed_authors>Divi V</pubmed_authors><pubmed_authors>Zdravkovic S</pubmed_authors><pubmed_authors>Sherman AR</pubmed_authors><pubmed_authors>Sunwoo JB</pubmed_authors><pubmed_authors>Rahman M</pubmed_authors><pubmed_authors>Lee MY</pubmed_authors><pubmed_authors>Stepanek I</pubmed_authors></additional><is_claimable>false</is_claimable><name>Single-cell spatial transcriptomics uncovers niches that govern response to PD-1/PD-L1 blockade in cutaneous squamous cell carcinoma.</name><description>&lt;h4>Background&lt;/h4>Neoadjuvant PD-1/PD-L1 blockade yields robust efficacy in advanced cutaneous squamous cell carcinoma (cSCC), yet many patients fail to achieve a complete or major pathologic response. The reasons why some patients experience response but others do not are unclear.&lt;h4>Methods&lt;/h4>We profiled cSCC specimens before, after 1 dose, and after 3-4 doses of PD-1/PD-L1 blockade to uncover resistance mechanisms and predict therapeutic response. In total, 27 patients across three cohorts, including two phase II trials, were studied. We created 1.7 mm tissue-core microarrays and performed single-cell spatial transcriptomics, including spatial clustering, gene-set enrichment, and spatial correlation analyses.&lt;h4>Results&lt;/h4>After profiling all samples, six distinct spatial niches eme</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-07-15T00:52:33.199Z</modification><creation>2026-06-27T03:05:39.415Z</creation></dates><accession>S-EPMC12863322</accession><cross_references><pubmed>41617396</pubmed><doi>10.1136/jitc-2025-014067</doi></cross_references></HashMap>